drugset / Trial / NCT04466215
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
Phase 2
Completed
50 enrolled
The Scripps Research Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
The hypotheses under test are that subjects with alcohol use disorder (AUD) of moderate or greater severity treated with CORT118335 will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.
Timeline
- Start
- 2021-04-15
- Primary completion
- 2022-04-15
- Completion
- 2022-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Miricorilant | Small molecule | 900 mg | Oral |